JP Patent

JP2022171838A — 重水素化ｊａｋ阻害剤による脱毛障害の処置

Assigned to Concert Pharmaceuticals Inc · Expires 2022-11-11 · 4y expired

What this patent protects

【課題】重水素化ＪＡＫ阻害剤による脱毛障害の処置を提供すること。【解決手段】哺乳動物対象の脱毛障害を処置する所定の方法。【選択図】なし

USPTO Abstract

【課題】重水素化ＪＡＫ阻害剤による脱毛障害の処置を提供すること。【解決手段】哺乳動物対象の脱毛障害を処置する所定の方法。【選択図】なし

Drugs covered by this patent

deuruxolitinib-phosphate (DEURUXOLITINIB PHOSPHATE)

Patent Metadata

Patent number: JP2022171838A
Jurisdiction: JP
Classification: —
Expires: 2022-11-11
Drug substance claim: No
Drug product claim: No
Assignee: Concert Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.